Status:
COMPLETED
A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza
Lead Sponsor:
Pfizer
Conditions:
Grippe
Influenza
Eligibility:
All Genders
18-84 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to anoth...
Eligibility Criteria
Inclusion
- Key
- \- Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
- Key
Exclusion
- \- Does not meet seasonal influenza vaccine requirements per cohort.
Key Trial Info
Start Date :
December 13 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 23 2025
Estimated Enrollment :
157 Patients enrolled
Trial Details
Trial ID
NCT06179446
Start Date
December 13 2023
End Date
September 23 2025
Last Update
November 14 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, United States, 06511
2
Research Centers of America
Hollywood, Florida, United States, 33024
3
NYU Langone Health
New York, New York, United States, 10016